RTSL — Rapid Therapeutic Science Laboratories Share Price
Last trade - 00:00- $0.03m
- $3.47m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.01 | 0 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rapid Therapeutic Science Laboratories, Inc. is a biopharmaceutical company. The Company is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company has developed a method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more patent pending pharmaceutical-grade cannabinoid compounds. It has developed and is continuing to develop a series of complementary products in addition to its inhaler. It is also focusing on manufacturing its own branded MDI under the nhaler brand name.
Directors
- Donal Schmidt PRE
- D. Hughes Watler CFO
- Ryan Johnson COO (46)
- Steve Bond DRC
- Brent Willson DRC
- Henry Punzi IND (63)
- Justin Suggs IND (52)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- February 22nd, 2013
- Public Since
- October 31st, 2013
- No. of Shareholders
- 130
- No. of Employees
- 3
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 18,986,917
- Address
- 558 County Road 472, DE LEON, 76444
- Web
- Phone
- +1 2142361363
- Auditors
- PWR CPA, LLPPWR CPA, LLP
Upcoming Events for RTSL
Similar to RTSL
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 16:53 UTC, shares in Rapid Therapeutic Science Laboratories are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Rapid Therapeutic Science Laboratories last closed at $0.00 and the price had moved by -65.12% over the past 365 days. In terms of relative price strength the Rapid Therapeutic Science Laboratories share price has underperformed the S&P500 Index by -72.78% over the past year.
There is no consensus recommendation for this security.
Find out moreRapid Therapeutic Science Laboratories does not currently pay a dividend.
Rapid Therapeutic Science Laboratories does not currently pay a dividend.
Rapid Therapeutic Science Laboratories does not currently pay a dividend.
To buy shares in Rapid Therapeutic Science Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Rapid Therapeutic Science Laboratories had a market capitalisation of $0.03m.
Here are the trading details for Rapid Therapeutic Science Laboratories:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RTSL
Based on an overall assessment of its quality, value and momentum Rapid Therapeutic Science Laboratories is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rapid Therapeutic Science Laboratories. Over the past six months, its share price has underperformed the S&P500 Index by -59.1%.
As of the last closing price of $0.00, shares in Rapid Therapeutic Science Laboratories were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rapid Therapeutic Science Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rapid Therapeutic Science Laboratories' management team is headed by:
- Donal Schmidt - PRE
- D. Hughes Watler - CFO
- Ryan Johnson - COO
- Steve Bond - DRC
- Brent Willson - DRC
- Henry Punzi - IND
- Justin Suggs - IND